Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
MWN-AI** Summary
Spectral Medical Inc. has updated its timeline regarding the Premarket Approval (PMA) submission for its hemoadsorption device, PMX-20R, intended to treat endotoxic septic shock. Originally anticipated for the first quarter of 2026, the submission is now expected to occur between late April and mid-May 2026. This change follows feedback from the U.S. Food and Drug Administration (FDA) that necessitated the inclusion of comprehensive 12-month mortality data from the Tigris study, along with the completion of non-clinical module items such as human factors engineering testing.
The Tigris Trial is a crucial phase of the PMX development, involving a 2:1 randomized study that compares PMX in addition to standard care against standard care alone. This trial aims to provide robust evidence for the efficacy of PMX, a therapeutic device that removes endotoxins from the bloodstream, which are known to trigger sepsis. CEO Chris Seto emphasized the company’s commitment to delivering a high-quality PMA submission and believes that the addition of long-term mortality data will strengthen the FDA’s review process.
The PMX device has already seen success abroad, being approved for therapeutic use in Japan and Europe and having sold over 360,000 units worldwide. In July 2022, the FDA granted Breakthrough Device Designation for PMX, which highlights its potential to address a significant medical need, given that approximately 330,000 patients in North America are diagnosed with septic shock each year.
Spectral Medical continues to collaborate closely with the FDA and will provide further updates on its PMA submission process as developments arise.
MWN-AI** Analysis
**Market Analysis and Advice for Spectral Medical Inc. (TSX: EDT)**
Spectral Medical Inc. continues to develop a robust narrative around its therapeutic hemoperfusion device, PMX, targeting a significant unmet need in the treatment of endotoxic septic shock. The recent update regarding the expected revision of its PMA submission timeline, now set for late April to mid-May 2026, draws attention to both regulatory interactions and clinical advancements in the company.
Investors should view this timeline adjustment positively, as the inclusion of comprehensive 12-month mortality data from the Tigris trial should bolster the efficacy narrative surrounding PMX. Given the device's unique mechanism of endotoxin removal, this extended data inclusion aligns with the FDA's stringent requirements for clinical evidence, potentially leading to a more favorable review outcome.
With approximately 330,000 patients diagnosed with septic shock annually in North America, the market opportunity for PMX remains substantial. The recent Breakthrough Device Designation from the FDA signifies a potential expedited review process, offering competitive advantage in what is likely to be a growing sector driven by increasing sepsis prevalence.
However, investors should remain cognizant of the inherent risks highlighted by management. The dependency on timely clinical trial completions and subsequent regulatory approvals can affect timelines and market performance. Maintaining awareness of these dynamics will be crucial for stakeholders as delays or complications could cause price volatility.
For current and prospective investors, a measured approach is advisable. Accumulating shares while continuing to monitor FDA interactions and trial data release schedules may provide an optimal strategy for those looking to capitalize on Spectral’s long-term potential. A diversified investment strategy, particularly in biopharma, can also mitigate risks associated with regulatory uncertainties inherent in companies like Spectral Medical.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock.
Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-May 2026, compared to its previously disclosed target of Q1 2026.
The updated timing reflects ongoing FDA feedback to incorporate complete 12-month mortality data from the Tigris study into the PMA submission, as well as the completion of certain non-clinical module items, including human factors engineering testing, to support a complete and compliant submission.
The Company believes the inclusion of complete 12-month mortality outcomes will further inform the FDA’s review and contribute to the totality of clinical evidence supporting PMX for the treatment of endotoxic septic shock.
Spectral currently anticipates being in a position to report topline 12-month mortality data in late May or early June 2026, subject to the completion of additional data analysis.
“We continue to work constructively with the FDA to ensure a high-quality PMA submission,” said Chris Seto, Chief Executive Officer of Spectral Medical. “The inclusion of longer-term mortality data and completion of the remaining non-clinical components are intended to support a comprehensive submission and will position PMX for an efficient review process.”
Spectral continues to work closely with the FDA on the PMA submission process and will provide updates as appropriate.
About Spectral
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood.
PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.
The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis https://www.youtube.com/watch?v=6RANrHHi9L8.
The trial methods are detailed in “Bayesian methods: a potential path forward for sepsis trials”.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
| Ali Mahdavi | Chris Seto |
| Capital Markets & Investor Relations | CEO |
| Spinnaker Capital Markets Inc. | Spectral Medical Inc. |
| 416-962-3300 | |
| am@spinnakercmi.com | cseto@spectraldx.com |
FAQ**
What are the specific reasons behind the delay of the Premarket Approval submission for Spectral Medical Inc EDTXF's hemoadsorption device to treat endotoxic septic shock, previously targeted for Q1 2026?
How will the inclusion of complete 12-month mortality data from the Tigris study enhance the FDA's evaluation of Spectral Medical Inc EDTXF’s PMA submission?
What are the potential implications for Spectral Medical Inc EDTXF if the FDA grants approval for the PMX device, considering the current annual septic shock diagnoses in North America?
Can you elaborate on the progress of the Tigris Trial and how its outcome will impact the future commercial strategy of Spectral Medical Inc EDTXF in the U.S. market?
**MWN-AI FAQ is based on asking OpenAI questions about Spectral Medical Inc (OTC: EDTXF).
NASDAQ: EDTXF
EDTXF Trading
4.75% G/L:
$0.997 Last:
1,000 Volume:
$0.997 Open:
